Published in:
Open Access
01-12-2014 | Meeting abstract
The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
Authors:
Megan MacRae, Stephanie Santucci, Jacob Karsh, William H Yang
Published in:
Allergy, Asthma & Clinical Immunology
|
Special Issue 2/2014
Login to get access
Excerpt
In a post-marketing analysis last updated in July 2007, the FDA reported that an estimated 0.2% of patients suffered treatment related anaphylaxis and rare incidence of serum sickness. To substantiate this, the occurrence of treatment related anaphylaxis and serum sickness in our large Canadian allergy and asthma tertiary clinic was assessed. …